Business Context and Reporting Period
Clene Inc. filed a Form 8-K dated May 5, 2022, reporting the results of its 2022 Annual Meeting of Stockholders. The filing was signed on May 6, 2022. Clene is an emerging growth company whose common stock and warrants trade on Nasdaq under CLNN and CLNNW, respectively.
Annual Meeting Results
| Proposal | Result | Vote Details |
|---|---|---|
| Election of David J. Matlin as Class I director | Approved | 33,485,551 for; 1,515,270 abstained; 9,616,981 broker non-votes |
| Election of John H. Stevens, M.D. as Class I director | Approved | 34,004,811 for; 996,010 abstained; 9,616,981 broker non-votes |
| Election of Chidozie Ugwumba as Class I director | Approved | 33,970,072 for; 1,030,749 abstained; 9,616,981 broker non-votes |
| Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal 2022 | Approved | 44,538,593 for; 77,826 against; 1,383 abstained; 1 broker non-vote |
Financial Metrics and Liquidity
This filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, balance-sheet data, or other operating financial metrics.
Material Changes, Outlook, and Risks
The filing reports no financial guidance, business outlook, management commentary, contingencies, unusual items, or material operating changes. The elected Class I directors will serve until the 2025 annual meeting and until their successors are elected and qualified.
Investor Verification Points
- Verify the final composition and term expirations of Clene’s board following the Class I director elections.
- Confirm Deloitte & Touche LLP’s appointment for the 2022 fiscal year.
- Review Clene’s related periodic filings for financial performance, cash runway, financing needs, clinical-program developments, and risk factors, which are not addressed in this 8-K.